Across TCGA pan-cancer cohorts, GJC3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GJC3 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher GJC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GJC3 expression acts as an unfavorable survival marker.
COAD are the cancer types where GJC3 Mutation most reproducibly stratifies survival.